Scientists at Jackson Laboratory developed a cocktail of non-neutralizing antibodies targeting overlapped epitopes of influenza A matrix protein, providing broad protection against diverse strains, including avian and swine variants. Unlike traditional neutralizing antibodies, this therapy tags infected lung cells for immune clearance, preventing viral escape over extended treatment windows. This approach challenges conventional thinking on antibody therapies and could transform influenza treatment and pandemic preparedness.